Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121394 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL14477978 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL119623 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL1283867 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL14477954 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL15082405 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL8084202 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL2890516 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL8084223 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL14477956 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2000512663-A | — | — | 2000-09-26 | — | — | JP | claimed |
| EP-1003469-A2 | FRAGRANCE PRECURSORS | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 2000-05-31 | — | — | EP | claimed |
| WO-1997030687-A2 | FRAGRANCE PRECURSORS | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1997-08-28 | — | — | WO | claimed |
| EP-2734180-B1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | OREAL (FR) | 2021-03-31 | — | — | EP | disclosed |
| US-20140294743-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | L'OREAL (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140294743-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | L'OREAL (FR) | 2014-10-02 | — | — | US | disclosed |
| WO-2013010590-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | L'OREAL (FR) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013011094-A2 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | L'OREAL (FR) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013001250-A2 | COSMETIC COMPOSITION INCLUDING A FUNCTIONALISED OIL AND A SOLVENT, AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2013-01-03 | — | — | WO | disclosed |
| WO-2011154458-A1 | COMPOSITION COMPRISING AT LEAST ONE 2-PYRROLIDONE FUNCTIONALIZED WITH AN ESTER OR AMIDE RADICAL, AND AT LEAST ONE PIGMENT OR DIRECT DYE, FOR DYEING KERATIN MATERIALS | L'OREAL (FR) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011154508-A1 | COSMETIC COMPOSITION COMPRISING A POLYMER AND A 4-CARBOXY-2-PYRROLIDINONE DERIVATIVE, COSMETIC TREATMENT PROCESS AND COMPOUND | L'OREAL (FR) | 2011-12-15 | — | — | WO | disclosed |
| EP-1003469-A2 | FRAGRANCE PRECURSORS | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 2000-05-31 | — | — | EP | disclosed |
| WO-1997030687-A2 | FRAGRANCE PRECURSORS | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294743-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | KRT18, LAGE3, TYR | POLB 2028/4885SMN1; SMN2 4825/4885L3MBTL1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.